| Literature DB >> 32982183 |
Anahita Jenab1, Rasoul Roghanian1, Giti Emtiazi1.
Abstract
Inflammation is part of the body's complex biological response to harmful stimuli such as damaged cells, pathogens, or irritants. It is a protective response inpan>volvinpan>g blood cells, immune cells, and molecular mediators. The inflammation not only can eliminate the primary cause of cell injury but also clears out necrotic cells, tissue damaged from the original insults and inflammatory process. Furthermore, it can initiate tissue repair. Pro-inflammatory cytokines are produced predominantly by activated macrophages and are involved in the up-regulation of inflammatory reactions. They are involved in further regulating inflammatory reactions. There is ample evidence that some pro-inflammatory cytokines, such as interleukin 1β (IL-1β), IL-6, and tumor necrosis factor-α (TNF-α), are involved in the pathological pain process. Some of the natural compounds promote cytokines production and inhibit inflammatory responses. The natural compounds which are produced from microorganisms such as omega-3 fatty acid, cyclic peptide, antimicrobial peptide, oligosaccharides, and polysaccharides can reduce inflammation and could be easily incorporated into the diet without any adverse effects. For example, SCFA (short-chain fatty acids), peptide bacteriocin, and polycyclic peptide bacteriocin (nisin) could be used in the treatment of atherosclerosis, orthopedic postoperative infections, and mycobacterium tuberculosis infection, respectively. Also, fatty acids (saturated and unsaturated fatty acids) can be introduced as anti-inflammatory drugs. This review article summarizes bacterial natural compounds with modulating effects on cytokines that are surveyed which may have potential anti-inflammatory drug-like activity.Entities:
Keywords: anti-inflammatory activity; bacterial natural materials; cytokine; drug-like activity; secondary metabolite
Mesh:
Substances:
Year: 2020 PMID: 32982183 PMCID: PMC7509312 DOI: 10.2147/DDDT.S261283
Source DB: PubMed Journal: Drug Des Devel Ther ISSN: 1177-8881 Impact factor: 4.162
Figure 1Schematic representation of the mechanisms in LPS-induced inflammation associated with iNOS and COX2.
Effects of Bacterial Bio-Active Materials Containing Peptide on Cytokine Production and Disease Therapy
| Producer | Bacterial Bio-Active Compound | Active Factors | Disease Therapy | Type | References |
|---|---|---|---|---|---|
| Biosurfactant | Increasing:IL10,TGF, | Anti-inflammatory drugs, food industry | Lipopeptide surfactant | ||
| YopM | Downregulating of TNF-α and interleukins 12, 15 and 18 | Anti-inflammatory | Cell-Penetrating Peptides (CPPs) | ||
| Bacteriocin | Decreasing of CRP, IL_6 | Treating or inhibitor of orthopedic postoperative infections | Peptides | ||
| Surfactin | Inhibition of the inflammatory agent’s production like IL-1β and iNOS. | Treating of septic shock | Cyclic lipopeptide | ||
| Iturin | Inhibition of inflammatory agents | Anti-inflammatory | Cyclic lipopeptide | ||
| LAB bacteria | Bacteriocin(nisin) | Down-regulating the lung Th2 response by increasing IFN-γ and reducing IL-4 &IL-13 | Anti-mycobacterial | Polycyclic antibacterial peptide | |
| Microcin MccJ25 (bacteriocin) | Increasing IL-6 & IL-10 Modulating of TNF-α and NF-κB | Against enterotoxigenic | Few amino acids |
Effects of Bacterial Bio-Active Materials Containing Fatty Acids on Cytokine Production and Disease Therapy
| Producer | Bacterial Bio-Active Compound | Active Factors | Disease Therapy | Type | References |
|---|---|---|---|---|---|
| EPA | Decreasing of inflammatory cytokine like (TNF)-α and IL-1β | Anti-inflammatory | Unsaturated fatty acids | ||
| Arachidonic acid | The inhibition of NO and TNF-α | Anti-inflammatory activity | Unsaturated fatty acids | ||
| Stearic acid | The inhibition of NO and TNF α | Anti-inflammatory activity | Saturated fatty acids | ||
| (Heneicosanoic acid) | The inhibition of NO and TNF α | Anti-inflammatory activity | Saturated fatty acids | ||
| Butyrate | It is inhibiting gene expression of inflammatory cytokines through modulating of MAPK signaling pathway and activation of NF-κB via activation fatty acid (FFA) receptors type 2, 3 (FFA2 and FFA3 receptors) and G protein-coupled receptor 109A (GPR109A) or inhibition of histone deacetylases (HDACs). | Treatment of atherosclerosis and sepsis | SCFA (Short-chain fatty acids): | ||
| Megasphaera massiliensis MRX0029 | Valeric acid(pentanoic acid) | Repression of IFN-γ, IL-10, IL-1β, TNF-α | Anti-inflammatory | SCFA(short-chain fatty acids) |
Effects of Other Bacterial Bio-Active Materials on Cytokine Production and Disease Therapy
| Producer | Bacterial Bio-Active Compound | Active Factors | Disease Therapy | Type | References |
|---|---|---|---|---|---|
| Bacteria isolated from soil samples in the beaches of Chennai, India(degrader chitin) | Chitosan:β(1–4) D- Glucosamine | No secretion of cytokine | None | Polysaccharide | |
| Lactic acid bacteria | Kefiran | Reducing IL-4 and IL-5 to normal levels | Treatment of inflammation of lung tissue | Polysaccharide | |
| Acetamido-amino-2,4,6-trideoxygalactose (AATGal) amino sugar | Induces IL_10 | attenuates TNBS-induced colitis | Polysaccharide Capsules in the intestine | ||
| IAA(derivation of (Indol)) | Anti-inflammatory possibility by its antioxidant activity | Mouse-ear edema | Acetyl derivatives | ||
| Dopamine(from the dietary substrate) | Modulating the immune system | Treating inflammatory diseases like IBD | An organic chemical of the catecholamine and phenethylamine families | ||
| Secondary metabolites of | Cold Bacillus metabolite (isolated −5°C) | Secondary metabolites of | Anti-inflammatory | Secondary metabolites of Bacillus sp isolated from Neogene permafrost | |
| CS1,CS2,CS3 belonging to genus | Equol((4ʹ,7-isoflavandiol)) | Reducing of IFNγ | Anti-inflammatory | isoflavandiol estrogen | |
| Butanol extract | Boosting of TNF-α and NO | Anti- colon cancer | Four-carbon alcohol | ||
| strain | Camporidine A | suppressing nitric oxide production | Anti-inflammatory | Polyketide alkaloid |
Figure 2Summary of the bacterial bio-active compounds, active components, their producing bacteria, and potential mechanism of their actions (anti-inflammatory).
Figure 3Summary of the bacterial bio-active compounds, active components, the potential mechanism of their actions, and treatment of different diseases.
Figure 4The downstream effect of short-chain fatty acids (SCFA) occurs with the regulation of MAPK signaling pathway and activation of NF-κB through two pathways: 1- activation of receptor FFA2, FFA3 receptors 2- inhibition of HDAC (histone deacetylase).46